World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
29317
World Ranking
16479
National Ranking
8282

Overview

Cathy Eng is affiliated with Vanderbilt University in the United States and focuses their research on medicine, particularly within oncology and related subfields. Their scholarly output includes 486 publications in medicine, with significant contributions in oncology (188 publications), surgery (97), pulmonary and respiratory medicine (83), pathology and forensic medicine (37), and cancer research (34).

The scientist's primary research topics encompass colorectal cancer treatments and studies, with 180 publications; gastric cancer management and outcomes, represented by 94 papers; colorectal and anal carcinomas, also appearing in 94 publications; genetic factors in colorectal cancer, studied in 66 works; cancer genomics and diagnostics, with 58 papers; cancer treatment and pharmacology, covered in 50 publications; and lung cancer treatments and mutations, addressed in 40 publications.

Cathy Eng frequently publishes in several well-known academic venues. These include the Journal of Clinical Oncology (61 publications), Annals of Oncology (13), The Oncologist (9), Cancers (8), and JCO Oncology Practice (5).

Their recent papers illustrate a focus on oncology and colorectal cancer management, including:

  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group (2020, The Oncologist)
  • Treatment of Metastatic Colorectal Cancer: ASCO Guideline (2022, Journal of Clinical Oncology)
  • Antiemetics: ASCO Guideline Update (2020, Journal of Clinical Oncology)
  • ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper (2020, Nature Reviews Clinical Oncology)
  • Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study (2023, The Lancet)

Collaboration is a notable component of this scientist's work. Frequent coauthors include Van K. Morris (37 joint publications), Arvind Dasari (30), Takayuki Yoshino (28), Josep Tabernero (27), and Sara Lonardi (22).

Best Publications

  • Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

    Jean Nicolas Vauthey;Timothy M. Pawlik;Dario Ribero;Tsung Teh Wu

  • Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

    Scott Kopetz;George J. Chang;Michael J. Overman;Cathy Eng

  • Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.

    Timothy M. Pawlik;Charles R. Scoggins;Daria Zorzi;Eddie K. Abdalla

  • EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer

  • Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

    Paul J. Hesketh;Mark G. Kris;Ethan Martin Basch;Kari Bohlke

  • A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

    Humaid O. Al-Shamsi;Waleed Alhazzani;Ahmad Alhuraiji;Eric A. Coomes

  • Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases

    Dan G. Blazer;Yoji Kishi;Dipen M. Maru;Scott Kopetz

  • Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

    Cathy Eng;Tae Won Kim;Johanna Bendell;Guillem Argilés

  • American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer.

    Sandra L. Wong;Pamela B. Mangu;Michael A. Choti;Todd S. Crocenzi

  • Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer

    In Ja Park;Y. Nancy You;Atin Agarwal;John M. Skibber

  • Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases

    Dario Ribero;Huamin Wang;Matteo Donadon;Daria Zorzi

  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

    Scott Kopetz;Paulo M. Hoff;Jeffrey S. Morris;Robert A. Wolff

  • High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome

    Antoine Brouquet;Eddie K. Abdalla;Scott Kopetz;Christopher R. Garrett

  • Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.

    Prajnan Das;John M. Skibber;Miguel A. Rodriguez-Bigas;Barry W. Feig

  • Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.

    Van K. Morris;Mohamed E. Salem;Halla Nimeiri;Syma Iqbal

  • ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.

    Arvind Dasari;Van K. Morris;Carmen J. Allegra;Chloe Atreya

  • Antiemetics: ASCO Guideline Update.

    Paul J. Hesketh;Mark G. Kris;Ethan Basch;Kari Bohlke

  • Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater

    Michael J. Overman;Gauri R. Varadhachary;Scott Kopetz;Rosni Adinin

  • Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes

    Jonathan M Loree;Allan Al Pereira;Michael Lam;Alexandra N Willauer

  • Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment

    M. P. Morelli;M. J. Overman;A. Dasari;S. M.A. Kazmi

Frequent Co-Authors

Michael J. Overman
Michael J. Overman The University of Texas MD Anderson Cancer Center
Scott Kopetz
Scott Kopetz The University of Texas MD Anderson Cancer Center
Robert A. Wolff
Robert A. Wolff The University of Texas MD Anderson Cancer Center
George J. Chang
George J. Chang The University of Texas MD Anderson Cancer Center
Miguel A. Rodriguez-Bigas
Miguel A. Rodriguez-Bigas The University of Texas MD Anderson Cancer Center
John M. Skibber
John M. Skibber The University of Texas MD Anderson Cancer Center
Christopher H. Crane
Christopher H. Crane Memorial Sloan Kettering Cancer Center
Sunil Krishnan
Sunil Krishnan The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam
Funda Meric-Bernstam The University of Texas MD Anderson Cancer Center
Filip Janku
Filip Janku The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens numerous alternative and related healthcare careers, many of which do not always require an MD. For instance, medical billing and coding online schools that accept financial aid offer flexible, in-demand programs that can be completed remotely, making healthcare roles accessible to more students.

Nursing is another popular route. Some do you have to take the teas test to get into nursing school programs have waived traditional entrance exams, streamlining entry into the field. If you’re interested in moving into healthcare management, consider a degree in healthcare administration, which can prepare you for non-clinical leadership roles in the industry.

Registered nurses seeking career growth may benefit from an advanced degree pathway such as an rn to np bridge. These programs accelerate qualified nurses into higher-level practitioner roles, combining clinical expertise with autonomy and increased earning potential.

Best Scientists Citing Cathy Eng

Trending Scientists

Recently Published Articles